Genmab partner receives conditional EU approval for cancer drug
The EU Commission has followed the recommendation of its expert panel and has granted Janssen conditional marketing authorization of Genmab's Rybrevant (amivantamab) for the treatment of advanced non-small cell lung cancer.
by marketwire, translated by daniel pedersen
Genmab's US partner Janssen has received conditional marketing authorization for amivantamab, marketed as Rybrevant, by the EU Commission, Genmab announces in a press release on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab pipeline hype makes investment bank uneasy
For subscribers
Anthony Mancini will help Genmab take its next steps
For subscribers
